Skip to content

GABAergic modulation of alpha and gamma oscillations: implications for working memory maintenance

GABAergic modulation of alpha and gamma oscillations: implications for working memory maintenance - GABAergic modulation of alpha and gamma oscillations

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON35861
Enrollment
30
Registered
2011-08-05
Start date
2011-11-24
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Working memory information maintenance Attention deficit hyperactivity disorder (ADHD) distraction

Interventions

GABA neurotransmission will be manipulated using the lorazepam in high (1.5mg), low doses (0.5mg) and placebo.

Sponsors

Radboud Universiteit Nijmegen
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: • Healthy volunteers between 18 and 35 years of age. • Predominant right-handedness

Exclusion criteria

Exclusion criteria: • Abnormal hearing or (uncorrected) vision. • Average use of more than 3 alcoholic beverages daily. • History of prescribed medication within the month prior to the start of the study • History of *over the counter* medication or cannabis usage within 2 months prior to the start of the study with exception of occasional use of paracetamol. • History of drug (opiate, LSD, (meth)amphetamine, cocaine, solvents, cannabis, or barbiturate) or alcohol dependence. • Average use of psychotropic medication or recreational drugs weekly or more. • Habitual smoking, i.e. more than a pack of cigarettes per week and a self-reported inability or unease to cease smoking for 24 hours prior to testing. • Use of psychotropic medication, or of recreational drugs over a period of 72 hours prior to each test session, and use of alcohol within the last 24 hours before each measurement. • Regular use of corticosteroids. • Metal objects in or around the body (braces, pacemaker, metal fragments, hearing devices). • (History of) psychiatric treatment. • (History of) neurological treatment. • (History of) endocrine treatment. • (History of) autonomic failure (e.g., vasovagal reflex syncope). • (History of) clinically significant hepatic, cardiac, obstructive respiratory, renal, cerebrovascular, metabolic or pulmonary disease. • (History of) epilepsy. • (History of) Raynaud*s syndrome. • Uncontrolled hypertension, defined as diastolic blood pressure at rest > 90 mmHg or systolic blood pressure at rest > 160 mmHg. • Hypotension, defined as diastolic blood pressure 30. • Claustrophobia. • Intense daily physical exercise. • Irregular sleep/wake rhythm (e.g., regular nightshifts or cross timeline travel). • Possible pregnancy or breastfeeding. • Increased risk for glaucoma.

Design outcomes

Primary

MeasureTime frame
Analysis of the oscillatory activity of alpha and gamma rhythms measured by MEG during the performance of the working memory task.

Secondary

MeasureTime frame
Mood questionnaires and blood pressure and heart rate.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)